Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.
Alain SarauxRené-Marc FlipoFrancis FagnaniJacques MassolGabrielle CukiermanJean-Michel JoubertPhilippe Huot-MarchandBernard G CombePublished in: RMD open (2021)
CDAI non-response at M3 is a predictor of failure to achieve the therapeutic target of LDA at M12 in patients with RA initiating treatment with CZP.